Table 1. Association between clinicopathological characteristics and GRP94 expression.
| Characteristics | GRP94 expression | P value | |
|---|---|---|---|
| Low (n = 52) | High (n = 39) | ||
| Gender | 0.770 | ||
| Male | 40 (77%) | 31 (79%) | |
| Female | 12 (23%) | 8 (21%) | |
| Mean Age (years) ± SD | 63.3 ± 7.9 | 66.0 ± 9.2 | 0.129 |
| Age | 0.328 | ||
| <65 years | 32 (62%) | 20 (51%) | |
| ≥65 years | 20 (38%) | 19 (49%) | |
| Grading of SCC | 0.327 | ||
| Well differentiated | 8 (15%) | 6 (15%) | |
| Moderately differentiated | 38 (73%) | 24 (62%) | |
| Poorly differentiated | 6 (12%) | 9 (23%) | |
| Invasive depth of tumor*1 | 0.395 | ||
| T1+T2 | 17 (34%) | 10 (26%) | |
| T3+T4 | 33 (66%) | 29 (74%) | |
| Lymph node metastasis*2 | |||
| Negative | 35 (70%) | 18 (47%) | 0.032 |
| Positive | 15 (30%) | 20 (53%) | |
| Stage (AJCC 7th Ed) *3 | 0.057 | ||
| I + II | 37 (77%) | 22 (58%) | |
| III + IV | 11 (23%) | 16 (42%) | |
*1 Missing data in 2 cases; *2 missing data in 3 cases; *3 missing data in 5 cases
Abbreviation: AJCC, American Joint Committee on Cancer